Metagenomi, Inc. Reports Q1 2025 Financial Results

Metagenomi, Inc. ( (MGX) ) just unveiled an announcement.

Metagenomi, Inc. announced its first quarter 2025 financial results and business updates, highlighting a study on Hemophilia A that showed sustained factor VIII activity in nonhuman primates over 19 months, indicating potential for long-term therapeutic effects. The company is well-capitalized with $226 million in cash and securities, expected to support operations into 2027, and continues to advance its AI-driven metagenomics platform, with plans for further studies and technological enhancements.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Spark’s Take on MGX Stock

According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.

Metagenomi, Inc. shows robust revenue growth, but significant challenges remain in profitability and cash flow management. The technical analysis indicates a bearish trend, while the valuation reflects potential financial distress due to negative earnings. Positive corporate developments provide some optimism, yet the overall financial and operational hurdles weigh heavily on the stock’s outlook.

To see Spark’s full report on MGX stock, click here.

More about Metagenomi, Inc.

Metagenomi, Inc. is a precision gene editing company that utilizes artificial intelligence and machine learning to develop potentially curative genome editing therapeutics. Their gene editing toolbox is derived from metagenomics and has the capability to target various genetic mutations across the human genome. The company focuses on developing therapies for conditions like Hemophilia A and has additional assets for secreted protein deficiencies and cardiometabolic diseases.

Average Trading Volume: 409,286

Technical Sentiment Signal: Sell

Current Market Cap: $57.94M

For a thorough assessment of MGX stock, go to TipRanks’ Stock Analysis page.